Menu
Back to Journals » Biologics: Targets and Therapy » Volume 7
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
Authors D'Arcangelo M, Cappuzzo F
Received 8 January 2013
Accepted for publication 25 January 2013
Published 3 March 2013 Volume 2013:7 Pages 61—68
DOI https://doi.org/10.2147/BTT.S28908
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Manolo D’Arcangelo,1,2 Federico Cappuzzo2
1Cancer Center, University of Colorado, Aurora (CO), USA; 2Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy
Abstract: Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.
Keywords: non-small cell lung cancer, MET, hepatocyte growth factor, ficlatuzumab, AV-299
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.